Background. The great clinical potential of myocardial b-AR imaging has been shown by recent studies evaluating the b-AR-specific, non-selective agent [
INTRODUCTION
The cardiac SNS affects fundamental features of cardiac function such as systolic contraction, diastolic relaxation, myocardial blood flow, and heart rate through pre-synaptic release of the neurotransmitter NE by sympathetic neurons and post-synaptic binding of NE to a-and b-AR on cardiac cells. Importantly, cardiac SNS dysfunction has been recognized to play major roles in the development of LV dysfunction, heart failure, and diabetic heart disease progression.
1,2 Pathophysiological modifications in b-AR density have been observed in a number of cardiac conditions 3 and more specifically in heart failure 1 and diabetic heart disease.
clinical settings such as non-ischemic cardiomyopathy and myocardial infarction. 4, 5 [ 11 C]-CGP12177 predicted the improvement of cardiac function in patients with idiopathic-dilated cardiomyopathy after long-term carvedilol treatment whereas dobutamine stress echocardiography did not, 6 and Gaemperli et al 7 found that reduced myocardial b-AR density early after myocardial infarction was associated with the incidence of congestive heart failure on long-term follow-up. In addition, recent studies have emphasized the clinical importance of assessing the presence of a potential mismatch in the cardiac SNS using agents targeted at the pre-and post-synaptic function. 8, 9 Although such studies have provided proof-of-concept that b-AR imaging has great potential clinical interest by itself or in combination with a pre-synaptic agent, the development of an [ 11 C]-labeled PET imaging agent is limited by the extremely short half-life of the isotope (20.4 
minutes).
b-Blockers labeled with radioactive isotopes of iodine and therefore suitable for SPECT imaging have not proven successful so far due to either suboptimal affinity for b-AR or high nonspecific binding associated with high lipophilicity. [10] [11] [12] [13] Studies performed with iodinated analogs of CGP-12177 also yielded negative results. 14 The aim of the present study was to perform the in vitro, ex vivo, and in vivo preclinical evaluation of AMI9, an analog of the b-AR ligand practolol, for the molecular nuclear imaging of b-AR density.
MATERIALS AND METHODS
The chemical structure of AMI9 is presented in Figure 1 . Primary cultures of NRCM were prepared and used as previously described 15 to perform radioligand displacement experiments and binding assays while isolated and perfused rat hearts were used to determine AMI9 and AMI9S pharmacological activities and swiss mice were used to evaluate 
RESULTS

Radioligand Displacement Experiments
Competition curves between [
3 H]-CGP-12177 and AMI9 or AMI9S are shown in Figure 2 . Both sets of data were best fitted monophasically, indicating a single class of affinity for b-AR. The competition curves between [ 3 H]-CGP-12177 and alprenolol (b), atenolol (b1), metoprolol (b1), pindolol (b), propranolol (b), and timolol (b) presented similar profiles. Corresponding K I , IC50, and RBA values are shown in Table 1 . The rank order of increasing RBA was atenolol \metoprolol; The results from competition experiments aimed at assessing the specificity and selectivity of [12 5 
Pharmacological Activity
Propranolol, AMI9, and AMI9S inhibited the isoproterenol-induced increase in dP/dt max of isolated perfused rat hearts in a dose-dependent manner (Table 3) . A significant inhibition of isoproterenol-induced increase in contractility was observed with 1 nM AMI9 and 10 nM AMI9S or propranolol. The concentrations of propranolol, AMI9, and AMI9S required to reach half-maximal inhibition of the isoproterenol-induced increase in dP/dt max (CID50) were 5.9 ± 0.8, 1.4 ± 0.5, and 3.7 ± 2.1 nM, respectively.
Lipophilicity
The log (P) value of AMI9 was .613. The retention coefficient (k 0 ) value of AMI9 (1.11) was lower than that of the lipophilic compound propranolol (1.43), comparable to that of the moderately lipophilic CGP-20712A (0.97) and higher than those of the hydrophilic compounds oxprenolol (0.78), CGP-12177 (0.13), and practolol (0.06). 
Biodistribution in Mice
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]-AMI9 Blood tracer activity was maximal immediately following injection (0.5 minute, DUR: 3.1 ± 0.1) and then rapidly decreased to stabilize at *1.2. In contrast, the cardiac radioactivity initially accumulated and peaked at 2 minutes p.i. (DUR: 5.3 ± 0.5) prior to decreasing (120 minutes, DUR: 0.5 ± 0.1). Pulmonary activity was twofold to sixfold higher than myocardial activity at all time points. The tracer was excreted predominantly through the kidneys with significant involvement of the hepatic route as well.
Low [
125 I]-AMI9 activities were observed in the brain, muscle, and fat (DUR range: brain, 0.1-0.3; muscle, 0.3-1.2; fat, 0.1-0.5).
[ 3 H]-CGP-12177 Blood tracer activity peaked immediately following injection (0.5 minute, DUR: 2.2 ± 0.2) and decreased slowly thereafter to reach a Table 3 . Dose-dependent inhibitory effects of propranolol, AMI9, and AMI9S on the dP/dt max of isolated rat hearts stimulated by 10 nM isoproterenol; dP/dt max values (mm HgÁsecond -1 ) expressed as mean ± SD; P value refers to the comparison between control perfusion (isoproterenol continuously) and continuous co (1.7 ± 0.8) 9 10 -7
(1.5 ± 1.0) 9 10
Prazosin (a 1 ) (1.1 ± 1.0) 9 10 -9
(3.7 ± 1.7) 9 10 Atropine (musc.) NC NC NC NC minimal value of 0.6 ± 0.1 at 120 minutes p.i. The cardiac activity followed approximately the same kinetic pattern. Early pulmonary activity was comparable to that observed following injection of [ 125 I]-AMI9 but remained elevated at later time points with lung uptake typically being fivefold to tenfold higher than cardiac uptake. The renal and hepatic routes were equally involved in tracer excretion and liver activity was lower than that of 
DISCUSSION
The affinity (K A ) of radiolabeled b-AR ligands for b-ARs should approximate 10 9 M -116 and the compounds should display b-blocker properties without inner sympathomimetic activity in order to form stable complexes with b-AR.
As observed for most b-blockers, the asymmetry of the carbon carrying the secondary alcohol function of the AMI9 compound generates two optical enantiomers R and S. Since the S enantiomer of aryloxypropanolamines is generally better recognized by b-AR than the R enantiomer, an original synthesis pathway was developed for the obtention of AMI9S. The results from the present study indicated that . The K D value for ICYP (0.4 ± 0.0 nM) was found to be higher by approximately one order of magnitude than values generally observed in the rat heart (22-29 pM) 19 while B max (290 ± 20 fmolÁ(mg protein) ).
[3H]-CGP-12177 displacement assays on NRCM allowed the comparison of RBA values for AMI9 and AMI9S with those of well-known b-blockers. The rank order of increasing affinity for b-AR was in overall accordance with previously published values. 21 RBA values of AMI9 and AMI9S were intermediary between those of metoprolol and propranolol. As the latter has an affinity considered as minimal for a potential b-AR SPECT radioligand (K D from 0.76 to 6 nM), 16, 22, 23 the affinity of AMI9 and AMI9S is therefore suitable for use as b-AR SPECT ligands. Saturation and kinetic binding studies gave similar K D values for AMI9 (5.6 ± 0.3 vs 4.5 nM, respectively) and AMI9S (3.1 ± 0.2 vs 2.6 nM, respectively). Affinity ratios between AMI9S and AMI9 (1.64, 1.79, and 1.75 depending on the binding study) were *2 (theoretical ratio) and therefore confirmed the expected better activity of the S enantiomer. Finally, the two-phase profiles of the competition curves between CGP-20712A or ICI 118551 and AMI9 or AMI9S provided evidence that AMI9 and AMI9S bind to both b1-and b2-AR. In addition, AMI9 and AMI9S poorly discriminated between b-AR subtypes as indicated by the results obtained with the one-site model used to fit the corresponding Scatchard curves. The B max values of AMI9 and AMI9S relative to NRCM b-AR were found to be identical, as expected for a racemic mixture in which the S enantiomer only binds to receptors. B max values of both radioligands were therefore intermediary between those of These results were in accordance with the moderate lipophilicity of AMI9, whose partition coefficient (log(P) = .61) was intermediary between that of CGP-12177 and ICYP (log(P) = -.52 and 1.26, respectively). 24 HPLC analysis confirmed the moderate lipophilic nature of AMI9, close to that of oxprenolol and CGP-20712A. AMI9 and AMI9S therefore appear well suited for those pathologies such as chronic heart failure in which global down-regulation of b-adrenoceptor expression occurs whereas their potential for diseases in which membrane receptors are being internalized will require further evaluation.
Results from specificity studies indicated that AMI9 and AMI9S bound to both b-and a-AR. Specificity ratios for CGP-20712A, ICI 118551, and prazosin from the present study were similar to those previously published. Indeed, b1:b2 ratios for CGP-20712A (580:1 and 380:1) were close to those described by Birnbaumer et al 25 (845:1) . Those for ICI 118551 (1:406 and 1:116) reflect the differences in the published ratios for this agent (1:54, 1:123, 1:225), [25] [26] [27] while the a1:a2 ratios for prazosin (3,220:1 and 450:1) were around the generally observed relative values (1,000:1 or 1,590:1). 28, 29 Human a-AR myocardial expression represents approximately 10% and 25% of total AR expression in nonfailing and failing human myocardium, respectively. 30 However, the potential poorer scintigraphic contrast resulting from AMI9 and AMI9S binding to a-AR and due to a higher number of targets (vessels, atria, platelets) does not theoretically constitute constraints for in vivo quantification of b-AR in SPECT because B max determination will mostly depend upon the highly specific nature of the cold ligand used to study nonspecific binding. In addition, the IC50 of AMI9 Table 1 ), indicating that AMI9 had a much lower affinity for a-AR than for b-AR. AMI9 binding to a-AR should therefore represent a minimal confounding actor while quantifying b-AR density from scintigraphic images.
b-AR imaging should avoid the use of b-AR agonists due to subsequent alterations in receptor conformation, binding dissociation, activation of intracellular reactions and consequently b-AR regulation mechanisms. Ligands should therefore display high bblocking potency without inner sympathomimetic activity. AMI9 and AMI9S demonstrated such properties in isolated perfused rat hearts. Indeed, both compounds inhibited the 10 nM isoproterenol-induced increase in contractility with a similar potency to that of propranolol without causing alterations in cardiac contractility when perfused alone at 1 lM (data not shown).
[ 3 H]-CGP-12177 and [ 125 I]-ICYP behaved as expected in in vivo mouse biodistribution studies. ICYP bound more than CGP-12177 to most tissues, likely due to the high lipophilicity of the former compound and therefore to its ability to bind to nonspecific targets as well as to all b-AR whereas the more hydrophilic CGP-12177 only bound to membrane receptors, resulting in lower heart uptake. [ 3 H]-CGP-12177 and [ 125 I]-ICYP cardiac activities that were obtained in mice in the present study were consistent with previously published data in rats when considering the differences in heart-toweight ratios between these two species. 31 The 3 H]-CGP12177 ratios were slightly superior afterward. These results suggest that the potential for in vivo b-AR density imaging with AMI9 should be further evaluated with special emphasis on early post-injection time points.
NEW KNOWLEDGE GAINED
Pathophysiological modifications in b-AR density have been observed in heart failure and diabetic heart disease. Although studies using [ 11 C]-CGP12177 have provided proof-of-concept that b-AR imaging has great potential clinical interest, the development of an [
11 C]-labeled PET imaging agent is limited by the extremely short half-life of the isotope. The present study showed that the iodinated b-blocker analog of practolol AMI9 as well as its S enantiomer AMI9S exhibited high affinity for b-AR in vitro and ex vivo together with moderate lipophilicity and that both compounds are therefore promising iodinated ligands for the in vivo assessment of myocardial b-adrenoceptor density.
CONCLUSION
The iodinated b-blocker analog of practolol AMI9 as well as its S enantiomer AMI9S exhibited high affinity for b-AR in vitro and ex vivo together with moderate lipophilicity. AMI9 is a promising iodinated ligand for the in vivo assessment of myocardial badrenoceptor density which requires further clinical evaluation.
